Drug intelligence / Profile preview

anti-FGF1 neutralizing antibody

Development stage
Unknown
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous, Subcutaneous, Intratumoral, Intraperitoneal, Parenteral
01

Overview

An anti-FGF1 neutralizing antibody is a monoclonal antibody designed to specifically bind to and inhibit the biological activity of Fibroblast Growth Factor 1 (FGF1), also known as acidic fibroblast growth factor. FGF1 is a member of the fibroblast growth factor family that plays a critical role in cell proliferation, survival, and angiogenesis by signaling through fibroblast growth factor receptors (FGFRs). In oncological research, particularly in melanoma, FGF1 is often secreted by tumor cells to promote autocrine growth and paracrine stimulation of endothelial cells, facilitating tumor vascularization. Neutralizing antibodies against FGF1 are utilized to sequester the growth factor in the extracellular environment, thereby blocking its interaction with FGFRs and suppressing downstream signaling pathways involved in tumor progression and angiogenesis.

Other names
anti-FGF1 antibodyanti-FGF-1 antibodyanti-FGF 1 antibodyFGF1 neutralizing antibodyFGF-1 neutralizing antibodyFGF 1 neutralizing antibody
02

Targets

FGF1 (Fibroblast growth factor 1)

Beyond the preview

Go deeper on anti-FGF1 neutralizing antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-FGF1 neutralizing antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call